SCHEMBL6102129

SCHEMBL6102129

CCCc1c(Cn2cc(C)nc2-c2cccc(F)c2)nn2ccc(C)nc12

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TLR8 Q9NR97 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ ADORA3 P0DMS8 1/20 0.33
▸ DCK P27707 1/20 0.32
▸ GCGR P47871 1/20 0.32
▸ F2RL3 Q96RI0 1/20 0.32
▸ KDM4E B2RXH2 2/20 0.32
▸ HSD17B10 Q99714 2/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ MAPT P10636 2/20 0.32
▸ LMNA P02545 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ ALOX15 P16050 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ PDE10A Q9Y233 1/20 0.32
▸ CYP1A2 P05177 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31
▸ CYP2C19 P33261 1/20 0.31
▸ PTGS2 P35354 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6101905 0.87 KDR (0.36) TLR8POLBMAPK1ADORA3GCGR
SCHEMBL6102485 0.84 DPP4 (0.32) PTGS2
SCHEMBL6101381 0.76 BRD4 (0.39) MAPK1ADORA3KDM4EALDH1A1MAPT
SCHEMBL6099356 0.75 PTGS2 (0.39) MAPK1GCGRKDM4EHSD17B10ALDH1A1
SCHEMBL6102198 0.72 HTR6 (0.39) BRD4
SCHEMBL6099817 0.71 ADORA3 (0.31) ADORA3GCGRKDM4EALDH1A1MEN1
SCHEMBL6101986 0.65 BRD4 (0.33) BRD4
SCHEMBL3072766 0.65 ENPP2 (0.40) POLBKDM4EALDH1A1MAPTLMNA
SCHEMBL3068662 0.65 KDM4E (0.44) KDM4E
SCHEMBL3059546 0.64 GRIN1 (0.41) KDM4EALDH1A1MAPTLMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130150351-A1 METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2013-06-13 — — US disclosed
US-20060014746-A1 Heteroaryl substituted fused bicyclic heteroaryl compounds as GABAA receptor ligands NEUROGEN CORPORATION 2006-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014746-A1 Heteroaryl substituted fused bicyclic heteroaryl compounds as GABAA receptor ligands GABRA5, GABRA2, GABBR1 TLR8 2371/4885POLB 4332/4885MAPK1 4600/4885
US-20130150351-A1 METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY GABBR2, GABBR1, GABRR3 TLR8 486/4885POLB 4627/4885MAPK1 2660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback